iCAD Hosting Technology Innovation Webinar on the Evolving Landscape for Treating Patients with Brain, Breast, and Rectal Cancers

Webinar Taking Place on Wednesday, October 21st @ 10am ET

NASHUA, N.H.,
Oct. 16, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that it will host a technology innovation webinar on the current
treatment landscape and unmet medical needs for treating cancer, on Wednesday,
October 21, 2020, at 10am Eastern Time.

The call will
feature presentations by key opinion leaders Santosh Kesari, MD, PhD, John
Wayne Cancer Center, Janie Grumley, MD, FACS, John Wayne Cancer Center and Té
Vuong, MD, B.Sc., Fountain Valley Regional Hospital & Medical Center, who
will discuss the current treatment landscape and new innovative methods for treating
patients with cancers such as glioblastoma (GBM), breast and rectal.

iCAD’s
management team will provide an update on innovations across the detection and
therapy businesses, including an overview of iCAD’s breast cancer
risk-assessment solution, a key element in the transformation from age-based
screening to risk-adaptive screening. Also highlighted will be recently
presented positive clinical data for Xoft® Brain IORT as a viable
treatment option for GBM. The management team, along with Drs. Vuong and Santosh
will be available to answer questions following the formal presentations.

To register for the event, please click here.

Janie Grumley,
MD, FACS, is the Director, Comprehensive Breast Program, Director at Margie
Petersen Breast Center and John Wayne Cancer Institute. She is a surgical breast
oncologist who has expertise in treating patients with breast cancer and benign
breast diseases. She specializes in novel treatments such as oncoplastic
breast-conserving surgery and intraoperative radiation therapy. Dr. Grumley
found her path in her third year of residency at the University of Southern
California when she met a surgical breast oncologist who was transforming
breast cancer care with the use of oncoplastic surgery. She was inspired by the
difference these techniques made in women’s lives during and after treatment.

Té Vuong, MD,
B.Sc., received her M.D. from the Université de Montréal and continued her
postgraduate training in radiation oncology at the University of Toronto and
the Institut Gustave Roussy and Institut Curie in Paris, France.

She is a
Professor at McGill University in the Department of Oncology, where she also
holds the position of Assistant Chair, Radiation Oncology. She was appointed
Director, Radiation Oncology of the Segal Cancer Centre at the Jewish General
Hospital in August 2009.

Dr. Vuong is
internationally recognized, particularly for her expertise in the treatment and
research of rectal cancer. Her current research focus is on high dose rate
endorectal brachytherapy for patients with rectal cancer. Her expertise makes
her a sought-after lecturer in both the academic and scientific communities.
Her publications appear in internationally renowned scientific journals.

Dr. Vuong
conducts cutting-edge research in the area of colorectal cancer. She has
engaged in numerous studies throughout her career, as either the Principal
Investigator or a co-participant. Her efforts have led to the development of
new radiation technologies and clinical protocols for the treatment of
gastrointestinal cancer.

Santosh
Kesari, MD, PhD, is a board-certified neurologist and neuro-oncologist and is
currently Chair and Professor, Department of Translational Neurosciences and
Neurotherapeutics, John Wayne Cancer Institute. He is also Director of
Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s
Health Center and Providence Little Company of Mary Medical Center Torrance,
and leads the Pacific Neuroscience Research Center at Pacific Neuroscience
Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists
in the nation, according to Castle Connolly Medical Ltd and an internationally
recognized scientist and clinician. He is a winner of an Innovation Award by
the San Diego Business Journal. He is on the advisory board of American Brain
Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund,
Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain
Tumor Alliance. He has been the author of over 250 scientific publications,
reviews, or books. He is the inventor on several patents and patent
applications, and founder and advisor to many cancer and neurosciences focused
biotech startups. In addition, he is a member of the Los Angeles Biomedical
Research Institute.

About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader
providing innovative cancer detection and therapy solutions.

The Xoft®
Axxent® Electronic Brachytherapy (eBx®) System®
is FDA-cleared, CE marked and licensed in a growing number of countries for the
treatment of cancer anywhere in the body. It uses a proprietary miniaturized
x-ray source to deliver a precise, concentrated dose of radiation directly to
the tumor site, while minimizing risk of damage to healthy tissue in nearby
areas of the body.

For more
information, visit www.icadmed.com and www.xoftinc.com.

Forward-Looking
Statements
Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the future prospects for the Company’s
technology platforms and products. Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited, to the Company’s ability to achieve business and strategic
objectives, the ability of IORT to provide flexibility, mobility or other
advantages, to be more beneficial for patients than traditional therapy or to
be accepted by patients or clinicians, the impact of supply and manufacturing
constraints or difficulties, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.

Contacts:
Media inquiries:
Jessica Burns, iCAD  
+1-201-423-4492
jburns@icadmed.com

Amy Cook, iCAD
acook@icadmed.com

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
jeremy@lifesciadvisors.com